Read closely, because we don't get to say this all too often: Valeant Pharmaceuticals' (NYSE: VRX) stock had a great day on Thursday. The embattled drugmaker, known for growing by acquisition, had lost 95% of its market value since …
Happening
Hedge fund billionaire John Paulson has joined the board of Valeant
MSN3d
Flirting
Finally, ValueAct Holdings L.P. boosted its position in Valeant Pharmaceuticals …
Stake
Stock has got OUTPERFORM rating from 1 of Thomson Reuters analysts, 13 given HOLD rating to the stock and 5 …
John Paulson
More than anything else, the company that made the iPod and iTunes wants its …
Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.74. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have given a buy rating and one has issued a …
Valeant Pharmaceuticals
Mizuho's Irina Koffler and Andrew Galler write that "despite the recent rally in VRX, [they] still expect the stock to drift towards our $8 PT due to our expectation of …
Following the transaction, the director now owns 70,572 shares of the company's …
John Paulson
Putting hard-earned dollars into an investment like Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock isn’t easy, especially since the stock has been nothing more than a weapon of wealth destruction. In August 2015, VRX stock